Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

pfizer pharmaceuticals inc. - lincomycin hydrochloride hydrate - dark blue opaque/pale blue opaque capsule

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacia limited company trading as pharmacia - lincomycin hydrochloride monohydrate equivalent to 250 mg lincomycin base;   - capsule - 250 mg - active: lincomycin hydrochloride monohydrate equivalent to 250 mg lincomycin base   excipient: lactose monohydrate magnesium stearate purified talc - indicated in the treatment of upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. effectiveness in the treatment of mastoiditis would be anticipated.

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin 300 mg in 1 ml - lincocin is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of cdad, as described in the boxed warning , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. indicated surgical procedures should be performed in conjunction with antibacterial therapy. lincocin may be administered concomitantly with other antimicrobial agents when indicated. lincocin is not indicated in the treatment of minor bacterial infections or viral infections. to reduce the development of drug-resistant bacteria and maintain the effectiveness of lincocin and other antibacterial drugs, lincocin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

United States - English - NLM (National Library of Medicine)

zoetis inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincocin products are indicated in infections caused by gram-positive organisms which are sensitive to its action, particularly streptococci and staphylococci. the drug has proven effective in eradicating causative organisms in most of the common upper respiratory tract infections, in septicemia, and in infections of the skin and adjoining tissues. systemic therapy with lincocin has been shown to be of benefit in many animals with pustular dermatitis. as with all antibiotics, in vitro sensitivity studies should be performed before lincocin is utilized as sole antibiotic therapy. lincocin has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and sensitive to lincomycin. the drug may be administered in combination therapy with other antimicrobial agents when indicated. no serious hypersensitivity reactions have been reported and many animals have received lincocin repeatedly without developing evidence of hypersensitivity. lincocin has demonstrated e

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - lincomycin hydrochloride monohydrate, quantity: 340.26 mg/ml (equivalent: lincomycin, qty 300 mg/ml) - injection, solution - excipient ingredients: benzyl alcohol; water for injections - indications as at 22 september 1994: lincocin is indicated in the treatment of serious infections due to susceptible strains of gram positive aerobes such as streptococci, pneumococci and staphylococci. its use should be reserved for penicillin allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. because of the risk of colitis (see precautions), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g.erythromycin). lincocin has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. staphylococcal strains resistant to lincocin have been recovered; culture and susceptibility studies should be done in conjunction with lincocin therapy. in the case of macrolides, partial but not complete cross resistance may occur. the drug may be administered concomitantly with other antimicrobial agents with

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - lincomycin hydrochloride monohydrate 340.26 mg/ml equivalent to lincomycin 300 mg/ml - solution for injection - 300 mg/ml - active: lincomycin hydrochloride monohydrate 340.26 mg/ml equivalent to lincomycin 300 mg/ml excipient: benzyl alcohol water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - lincomycin hydrochloride -

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

lincomycin 500mg

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

lincomycin hcl 500mg

Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis belgium s.a. - lincomycin hydrochloride - powder for use in drinking water - 400 milligram(s)/gram - lincomycin - pigs - antibacterial